Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: July 19, 2006
Last updated: July 3, 2011
Last verified: June 2011
We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.

Acute Coronary Syndrome
Venous Thromboembolism
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 500
Study Start Date: July 2006
Estimated Study Completion Date: October 2015
Detailed Description:
Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients admitted to tertiary hospital

Inclusion Criteria:

  • treatment with enoxaparin

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00354796

Contact: Mordechai Muszkat, MD 00-972-2-6776449

Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD    00 972 2 6776095   
Contact: hadas Lemberg, PhD    00 972 2 6777572   
Principal Investigator: Mordechai Muszkat, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Mordechai Muszkat, MD Hadassah University Hospital
  More Information

Responsible Party: Mordechai Muszkat, Hadassah University Hospital Identifier: NCT00354796     History of Changes
Other Study ID Numbers: enoxap-HMO-CTIL
Study First Received: July 19, 2006
Last Updated: July 3, 2011

Keywords provided by Hadassah Medical Organization:

Additional relevant MeSH terms:
Atrial Fibrillation
Acute Coronary Syndrome
Venous Thromboembolism
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Myocardial Ischemia
Vascular Diseases
Embolism and Thrombosis
Hematologic Diseases processed this record on May 22, 2017